Study S001780

The Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01392898
Acronym: ELEGANT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 50
Start: 2012-02
Primary completion: 2014-05
Lead sponsor: Radboud University Medical Center
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:liraglutide; DRUG:Insulin
Results posted: FALSE

Registered primary outcomes

Body weight change (measured body weight at 26 weeks minus baseline body weight) [26 weeks (26 weeks - baseline)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025175	Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). de Wit HM, Diabetologia	2014	Randomized trial	PMID 24947583 DOI	cites ClinicalTrials.gov:NCT01392898; registry reference DERIVED:24947583